5th Circuit Blocks Nationwide Remote Access to Abortion Medication, Upholding Louisiana’s Abortion Ban
Why It Matters
A federal appeals court ruling issued Friday deals a significant blow to the network of telehealth workarounds that abortion providers in permissive states had used to circumvent abortion bans in states like Louisiana. The decision directly reinforces Louisiana’s authority to enforce its prohibition on medication-based abortions and restores restrictions on the remote dispensing of mifepristone that the Biden administration had loosened.
For the 13 states with near-total abortion bans currently in effect, the ruling means residents seeking to terminate a pregnancy will once again be required to travel to another state in person — eliminating a significant loophole that had allowed the medication to be mailed across state lines under so-called “shield laws.”
What Happened
The 5th Circuit Court of Appeals on Friday blocked a 2023 U.S. Food and Drug Administration rule that had allowed mifepristone — one of two drugs used to end a pregnancy before 10 weeks — to be dispensed without an in-person visit to a health care provider. The drug is also used in miscarriage treatment.
The ruling stems from a lawsuit filed in October by Louisiana Attorney General Liz Murrill, a Republican, who sued the FDA seeking to strike down the 2023 provision. A lower court initially declined to block the rule in early April, with U.S. District Judge David C. Joseph ruling the stay premature while the FDA completed a safety review. Louisiana appealed that decision to the 5th Circuit, which sided with the state.
The three-judge panel — comprising Judge Leslie Southwick, Judge Stuart Kyle Duncan, and Judge Kurt D. Engelhardt — issued no dissenting opinions. Duncan and Engelhardt are appointees of President Donald Trump; Southwick was appointed by former Republican President George H.W. Bush.
In its decision, the court wrote that “every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions and undermines its policy that ‘every unborn child is human being from the moment of conception and is, therefore, a legal person.'”
Attorney General Murrill welcomed the ruling, stating that the Biden administration had facilitated “illegal mail-order abortion pills” and crediting her office and the Alliance Defending Freedom with securing the outcome. “I look forward to continuing to defend women and babies as this case continues,” Murrill said in a statement.
By the Numbers
- 27%+ of all abortions were provided through telehealth appointments in the first six months of 2025, according to the Society of Family Planning.
- ~15,000 abortions per month were provided under shield laws during the same period.
- 13 states currently have near-total abortion bans where residents will now be required to travel out of state for abortion access.
- $92,000 in Louisiana Medicaid funds were spent on emergency care for two women in 2025 who experienced complications the state attributed to out-of-state mifepristone — a figure the court cited as a tangible injury to the state.
- Less than 1% of mifepristone users experienced severe complications requiring hospitalization or blood transfusion, according to a combined review of studies conducted between 2005 and 2015.
Zoom Out
The ruling represents a pivotal development in the post-Dobbs legal landscape, in which states with abortion bans have sought to close cross-border access gaps while states with legal abortion have built infrastructure to serve out-of-state patients. Telehealth prescriptions and mail delivery had become one of the primary mechanisms for circumventing state bans — a workaround that Friday’s decision effectively dismantles on a nationwide basis.
The block on the FDA rule will remain in place while the underlying lower court case continues. The FDA retains the option to file an emergency appeal to the U.S. Supreme Court in the coming weeks, which could potentially stay or reverse the 5th Circuit’s action.
What’s Next
The most immediate question is whether the FDA — operating under the Trump administration — will pursue an emergency appeal to the Supreme Court. Legal observers expect the lower court case to continue under the new restrictions, with further rulings possible depending on the outcome of the FDA’s ongoing safety review of mifepristone.
State officials and legal organizations on both sides of the issue are expected to file additional briefs as the case progresses. Louisiana’s enforcement of its abortion ban, which has been a continued source of legal and political conflict, remains at the center of the national debate over abortion access.